Celanese revises revolving credit facility, lowers Q2 earnings and revenue forecasts.

Celanese has revised its revolving credit facility and reported Q2 adjusted earnings and revenue that fell short of expectations. The company's shares declined after hours. Celanese expects Q3 adjusted EPS of $1.10-$1.40. The chemical maker has also partnered with Bentley Mills and Meliodays for sustainable carpet tile manufacturing and hormone-free non-contraceptive IUD development, respectively. Celanese has maintained its quarterly dividend at $0.03 a share and has been added to and dropped from various Russell indices.

Celanese Corporation (CE) reported its second-quarter (Q2) adjusted earnings per share (EPS) of $1.44, which fell short of the analyst estimate of $1.40. Revenue for the quarter came in at $2.53 billion, surpassing the consensus estimate of $2.5 billion. The company's stock price closed at $47.42, down -9.17% in the last three months and -62.12% in the last 12 months [2].

Celanese expects its third-quarter (Q3) adjusted EPS to range between $1.10 and $1.40, which is below the analyst consensus of $1.73. The company attributed the lower-than-expected Q2 earnings to challenges in the environment across most key end-markets in the second half of the year [3].

In addition to its financial performance, Celanese has been active in sustainable initiatives. The company has partnered with Bentley Mills to adopt its VAE ECO-CC emulsion, an innovative binder manufactured using captured carbon dioxide, for carpet tile production. Additionally, Celanese has entered a partnership with Meliodays Medical to apply its VitalDose Drug Delivery Platform to a new hormone-free IUD for menstrual pain relief [4].

Celanese has maintained its quarterly dividend at $0.03 a share. To earn $500 monthly from Celanese, an investor would need to own approximately 6,000 shares, or $2,432,500 worth of the stock [1].

Celanese's stock has experienced volatility. Over the past month, shares of Celanese have returned -18.2% versus the Zacks S&P 500 composite's +0.5% change. Currently, CE carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future [1].

References:
[1] https://www.nasdaq.com/articles/exploring-analyst-estimates-celanese-ce-q2-earnings-beyond-revenue-and-eps
[2] https://www.investing.com/news/earnings/celanese-earnings-beat-by-004-revenue-topped-estimates-4183708
[3] https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3U3198:0-celanese-slumps-on-lower-than-expected-quarterly-profit-forecast/
[4] https://simplywall.st/stocks/us/materials/nyse-ce/celanese/news/will-celaneses-ce-bet-on-sustainability-and-drug-delivery-re